Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institutes of Health's National Cancer Institute is soliciting grant applications for early-stage innovative technology development to support basic and clinical cancer research. Supported projects must focus on proof-of-concept and pilot studies to test the technical feasibility of methods, tools, assays, platforms, or instruments that can measure, analyze, model, or interrogate cancer-related systems. To be considered, proposals must demonstrate a high degree of technical innovation with potential applications in cancer biology, early detection, treatment, or epidemiology. The opportunity has an estimated total program funding of $5,400,000 to support approximately 23 awards, with an individual award ceiling of $150,000. Applications are estimated to close on June 4, 2027, and inquiries can be directed to the IMAT Program Contact at 240-255-0917 or NCI-IMAT@nih.gov.
Eligible Applicants
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Grant Documents
No documents available for this grant.